The European Medicines Agency (EMA) has granted its first approval for a treatment targeting the underlying processes of Alzheimer’s disease. The antibody Lecanemab is authorized for individuals with mild cognitive impairment or early-stage dementia. Produced by Biogen’s Swiss branch, this…

The European Medicines Agency (EMA) has approved Leqembi, a groundbreaking treatment for Alzheimer’s disease, for patients not yet in advanced stages. Initially blocked in July due to concerns over severe side effects, the drug is now recommended for those at…